Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer

Exclusion Criteria

• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •GOG 0-2
• •Life expectancy
• •Not specified
• •Hematopoietic
• •Absolute neutrophil count ≥ 1,500/mm\^3
• •Platelet count ≥ 100,000/mm\^3
• •Hepatic
• •Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• •SGOT ≤ 2.5 times ULN
• •Alkaline phosphatase ≤ 2.5 times ULN
• •Renal
• •Creatinine ≤ 1.5 times ULN
• •Other
• •Sensory or motor neuropathy ≤ grade 1
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No active infection requiring antibiotics
• •No other malignancy within the past 5 years except nonmelanoma skin cancer
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •One prior non-cytotoxic (biologic or cytostatic) regimen for recurrent or persistent disease allowed, including, but not limited to, the following:
• •* Monoclonal antibodies
• •* Cytokines
• •* Small-molecule inhibitors of signal transduction
• •At least 3 weeks since prior biologic or immunologic agents for cervical cancer
• •No concurrent prophylactic growth factors, including filgrastim (G-CSF), sargramostim (GM-CSF), or pegfilgrastim
• •No concurrent prophylactic thrombopoietic agents
• •Chemotherapy
• •See Disease Characteristics
• •Recovered from prior chemotherapy
• •No more than 1 prior cytotoxic chemotherapy regimen (either with single or combination cytotoxic drug therapy)
• •No prior topotecan
• •Endocrine therapy
• •At least 1 week since prior hormonal therapy for cervical cancer
• •Concurrent hormone replacement therapy allowed
• •Radiotherapy
• •See Disease Characteristics
• •Recovered from prior radiotherapy
• •Surgery
• •Recovered from prior surgery
• •Other
• •At least 3 weeks since other prior therapy for cervical cancer
• •No prior cancer therapy that would preclude study participation